| Year |
Citation |
Score |
| 2016 |
Petrou P, Gothelf Y, Argov Z, Gotkine M, Levy YS, Kassis I, Vaknin-Dembinsky A, Ben-Hur T, Offen D, Abramsky O, Melamed E, Karussis D. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. Jama Neurology. 1-8. PMID 26751635 DOI: 10.1001/jamaneurol.2015.4321 |
0.31 |
|
| 2015 |
Benninger F, Khlebtovsky A, Roditi Y, Keret O, Steiner I, Melamed E, Djaldetti R. Beneficial effect of levodopa therapy on stooped posture in Parkinson's disease. Gait & Posture. 42: 263-8. PMID 26055804 DOI: 10.1016/j.gaitpost.2015.05.015 |
0.305 |
|
| 2015 |
Lev N, Barhum Y, Ben-Zur T, Aharony I, Trifonov L, Regev N, Melamed E, Gruzman A, Offen D. A DJ-1 Based Peptide Attenuates Dopaminergic Degeneration in Mice Models of Parkinson's Disease via Enhancing Nrf2. Plos One. 10: e0127549. PMID 26024237 DOI: 10.1371/journal.pone.0127549 |
0.381 |
|
| 2014 |
Lamm O, Ganz J, Melamed E, Offen D. Harnessing neurogenesis for the possible treatment of Parkinson's disease. The Journal of Comparative Neurology. 522: 2817-30. PMID 24723264 DOI: 10.1002/cne.23607 |
0.408 |
|
| 2014 |
de Munter JP, Melamed E, Wolters ECh. Stem cell grafting in parkinsonism--why, how and when. Parkinsonism & Related Disorders. 20: S150-3. PMID 24262169 DOI: 10.1016/S1353-8020(13)70036-1 |
0.317 |
|
| 2013 |
Greenbaum L, Lorberboym M, Melamed E, Rigbi A, Barhum Y, Kohn Y, Khlebtovsky A, Lerer B, Djaldetti R. Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease. Frontiers in Neuroscience. 7: 52. PMID 23596382 DOI: 10.3389/fnins.2013.00052 |
0.393 |
|
| 2013 |
Lev N, Barhum Y, Ben-Zur T, Melamed E, Steiner I, Offen D. Knocking out DJ-1 attenuates astrocytes neuroprotection against 6-hydroxydopamine toxicity. Journal of Molecular Neuroscience : Mn. 50: 542-50. PMID 23536331 DOI: 10.1007/s12031-013-9984-9 |
0.379 |
|
| 2013 |
Lang AE, Melamed E, Poewe W, Rascol O. Trial designs used to study neuroprotective therapy in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 86-95. PMID 22927060 DOI: 10.1002/mds.24997 |
0.331 |
|
| 2013 |
Lev N, Barhum Y, Pilosof NS, Ickowicz D, Cohen HY, Melamed E, Offen D. DJ-1 protects against dopamine toxicity: implications for Parkinson's disease and aging. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. 68: 215-25. PMID 22887838 DOI: 10.1093/gerona/gls147 |
0.429 |
|
| 2012 |
Dadon-Nachum M, Ben-Zur T, Srugo I, Shamir HM, Melamed E, Yaffe D, Offen D. Therapeutic effect of myogenic cells modified to express neurotrophic factors in a rat model of sciatic nerve injury. Journal of Stem Cells & Regenerative Medicine. 8: 21-7. PMID 24693189 DOI: 10.46582/Jsrm.0801004 |
0.322 |
|
| 2012 |
Shruster A, Ben-Zur T, Melamed E, Offen D. Wnt signaling enhances neurogenesis and improves neurological function after focal ischemic injury. Plos One. 7: e40843. PMID 22815838 DOI: 10.1371/journal.pone.0040843 |
0.301 |
|
| 2012 |
Khlebtovsky A, Rigbi A, Melamed E, Ziv I, Steiner I, Gad A, Djaldetti R. Patient and caregiver perceptions of the social impact of advanced Parkinson's disease and dyskinesias. Journal of Neural Transmission (Vienna, Austria : 1996). 119: 1367-71. PMID 22437202 DOI: 10.1007/s00702-012-0796-9 |
0.305 |
|
| 2012 |
Sadan O, Shemesh N, Barzilay R, Dadon-Nahum M, Blumenfeld-Katzir T, Assaf Y, Yeshurun M, Djaldetti R, Cohen Y, Melamed E, Offen D. Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington's disease. Experimental Neurology. 234: 417-27. PMID 22285250 DOI: 10.1016/j.expneurol.2011.12.045 |
0.355 |
|
| 2012 |
Melamed E, Poewe W. Taking sides: is handedness involved in motor asymmetry of Parkinson's disease? Movement Disorders : Official Journal of the Movement Disorder Society. 27: 171-3. PMID 22223083 DOI: 10.1002/mds.24048 |
0.313 |
|
| 2012 |
Lev N, Barhum Y, Ben-Tzur T, Melamed E, Offen D. DJ-1 Based Peptide as a Novel Neuroprotective Strategy for Parkinson's Disease (SC02.003) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.Sc02.003 |
0.378 |
|
| 2011 |
Barzilay R, Ben-Zur T, Sadan O, Bren Z, Taler M, Lev N, Tarasenko I, Uzan R, Gil-Ad I, Melamed E, Weizman A, Offen D. Intracerebral adult stem cells transplantation increases brain-derived neurotrophic factor levels and protects against phencyclidine-induced social deficit in mice. Translational Psychiatry. 1: e61. PMID 22832353 DOI: 10.1038/tp.2011.64 |
0.323 |
|
| 2011 |
Ganz J, Lev N, Melamed E, Offen D. Cell replacement therapy for Parkinson's disease: how close are we to the clinic? Expert Review of Neurotherapeutics. 11: 1325-39. PMID 21864078 DOI: 10.1586/ern.11.74 |
0.392 |
|
| 2011 |
Vilariño-Güell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, Soto-Ortolaza AI, Cobb SA, Wilhoite GJ, Bacon JA, Behrouz B, Melrose HL, Hentati E, Puschmann A, Evans DM, ... ... Melamed E, et al. VPS35 mutations in Parkinson disease. American Journal of Human Genetics. 89: 162-7. PMID 21763482 DOI: 10.1016/j.ajhg.2011.06.001 |
0.308 |
|
| 2011 |
Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. The Lancet. Neurology. 10: 415-23. PMID 21482191 DOI: 10.1016/S1474-4422(11)70073-4 |
0.312 |
|
| 2011 |
Dadon-Nachum M, Sadan O, Srugo I, Melamed E, Offen D. Differentiated mesenchymal stem cells for sciatic nerve injury. Stem Cell Reviews. 7: 664-71. PMID 21327572 DOI: 10.1007/s12015-010-9227-1 |
0.328 |
|
| 2011 |
Inzelberg R, Rabey JM, Melamed E, Djaldetti R, Reches A, Badarny S, Hassin-Baer S, Cohen O, Trau H, Aharon-Peretz J, Milo R, Schwartz M, Huberman M, Gilead L, Barchana M, et al. High prevalence of malignant melanoma in Israeli patients with Parkinson's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 118: 1199-207. PMID 21298300 DOI: 10.1007/S00702-011-0580-2 |
0.329 |
|
| 2011 |
Shruster A, Eldar-Finkelman H, Melamed E, Offen D. Wnt signaling pathway overcomes the disruption of neuronal differentiation of neural progenitor cells induced by oligomeric amyloid β-peptide. Journal of Neurochemistry. 116: 522-9. PMID 21138436 DOI: 10.1111/j.1471-4159.2010.07131.x |
0.308 |
|
| 2011 |
Dadon-Nachum M, Melamed E, Offen D. The "dying-back" phenomenon of motor neurons in ALS. Journal of Molecular Neuroscience : Mn. 43: 470-7. PMID 21057983 DOI: 10.1007/s12031-010-9467-1 |
0.316 |
|
| 2011 |
Djaldetti R, Lorberboym M, Karmon Y, Treves TA, Ziv I, Melamed E. Residual striatal dopaminergic nerve terminals in very long-standing Parkinson's disease: a single photon emission computed tomography imaging study. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 327-30. PMID 20939078 DOI: 10.1002/mds.23380 |
0.394 |
|
| 2011 |
Kan I, Barhum Y, Melamed E, Offen D. Mesenchymal stem cells stimulate endogenous neurogenesis in the subventricular zone of adult mice. Stem Cell Reviews. 7: 404-12. PMID 20830611 DOI: 10.1007/s12015-010-9190-x |
0.302 |
|
| 2010 |
Hellmann MA, Melamed E, Steinmetz AP, Djaldetti R. Unilateral lower limb rest tremor is not necessarily a presenting symptom of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 924-7. PMID 20198647 DOI: 10.1002/mds.23030 |
0.359 |
|
| 2010 |
Shemesh N, Sadan O, Melamed E, Offen D, Cohen Y. Longitudinal MRI and MRSI characterization of the quinolinic acid rat model for excitotoxicity: peculiar apparent diffusion coefficients and recovery of N-acetyl aspartate levels. Nmr in Biomedicine. 23: 196-206. PMID 19950122 DOI: 10.1002/nbm.1443 |
0.339 |
|
| 2010 |
Sadan O, Shemesh N, Melamed E, Offen D, Cohen Y. I11 Longitudinal MRI and MRSI characterisation of the quinolinic acid rat model for excitotoxicity: unique recovery of N-acetyl aspartate levels Journal of Neurology, Neurosurgery & Psychiatry. 81: A39.3-A39. DOI: 10.1136/jnnp.2010.222679.11 |
0.339 |
|
| 2010 |
Sadan O, Shemesh N, Cohen Y, Melamed E, Offen D. B15 Rat bone marrow derived mesenchymal stem cells post differentiation to neurotrophic factor secreting cells migrate towards quinolinic acid lesion Journal of Neurology, Neurosurgery & Psychiatry. 81: A15.3-A16. DOI: 10.1136/jnnp.2010.222596.15 |
0.337 |
|
| 2010 |
Sadan O, Barzilay R, Melamed E, Offen D. B14 Neurotrophic factors secreting mesenchymal stem cells attenuate quinolinic acid induced striatal lesion model suggesting autologous therapy for HD Journal of Neurology, Neurosurgery & Psychiatry. 81: A15.2-A15. DOI: 10.1136/jnnp.2010.222596.14 |
0.352 |
|
| 2009 |
Djaldetti R, Treves TA, Ziv I, Melamed E, Lampl Y, Lorberboym M. Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 30: 301-5. PMID 19499179 DOI: 10.1007/s10072-009-0100-4 |
0.362 |
|
| 2009 |
Barzilay R, Ben-Zur T, Bulvik S, Melamed E, Offen D. Lentiviral delivery of LMX1a enhances dopaminergic phenotype in differentiated human bone marrow mesenchymal stem cells. Stem Cells and Development. 18: 591-601. PMID 19298173 DOI: 10.1089/scd.2008.0138 |
0.302 |
|
| 2009 |
Sadan O, Bahat-Stromza M, Barhum Y, Levy YS, Pisnevsky A, Peretz H, Ilan AB, Bulvik S, Shemesh N, Krepel D, Cohen Y, Melamed E, Offen D. Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease. Stem Cells and Development. 18: 1179-90. PMID 19243240 DOI: 10.1089/scd.2008.0411 |
0.404 |
|
| 2009 |
Djaldetti R, Lev N, Melamed E. Lesions outside the CNS in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 793-800. PMID 19224610 DOI: 10.1002/mds.22172 |
0.371 |
|
| 2009 |
Bahat-Stroomza M, Barhum Y, Levy YS, Karpov O, Bulvik S, Melamed E, Offen D. Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease. Journal of Molecular Neuroscience : Mn. 39: 199-210. PMID 19127447 DOI: 10.1007/s12031-008-9166-3 |
0.408 |
|
| 2009 |
Lev N, Ickowicz D, Barhum Y, Lev S, Melamed E, Offen D. DJ-1 protects against dopamine toxicity. Journal of Neural Transmission (Vienna, Austria : 1996). 116: 151-60. PMID 18974921 DOI: 10.1007/s00702-008-0134-4 |
0.417 |
|
| 2008 |
Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E, Rascol O. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 2194-201. PMID 18932271 DOI: 10.1002/mds.22218 |
0.31 |
|
| 2008 |
Djaldetti R, Hassin-Baer S, Farrer MJ, Vilariño-Güell C, Ross OA, Kolianov V, Yust-Katz S, Treves TA, Barhum Y, Hulihan M, Melamed E. Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel. Journal of Neural Transmission (Vienna, Austria : 1996). 115: 1279-84. PMID 18665323 DOI: 10.1007/s00702-008-0074-z |
0.327 |
|
| 2008 |
Sadan O, Shemesh N, Barzilay R, Bahat-Stromza M, Melamed E, Cohen Y, Offen D. Migration of neurotrophic factors-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imaging. Stem Cells (Dayton, Ohio). 26: 2542-51. PMID 18635865 DOI: 10.1634/stemcells.2008-0240 |
0.32 |
|
| 2008 |
Levy YS, Bahat-Stroomza M, Barzilay R, Burshtein A, Bulvik S, Barhum Y, Panet H, Melamed E, Offen D. Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease. Cytotherapy. 10: 340-52. PMID 18574767 DOI: 10.1080/14653240802021330 |
0.375 |
|
| 2008 |
Barzilay R, Kan I, Ben-Zur T, Bulvik S, Melamed E, Offen D. Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols. Stem Cells and Development. 17: 547-54. PMID 18513164 DOI: 10.1089/scd.2007.0172 |
0.403 |
|
| 2008 |
Lev N, Ickowicz D, Melamed E, Offen D. Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection. Neurotoxicology. 29: 397-405. PMID 18377993 DOI: 10.1016/j.neuro.2008.01.007 |
0.348 |
|
| 2008 |
Yust-Katz S, Tesler D, Treves TA, Melamed E, Djaldetti R. Handedness as a predictor of side of onset of Parkinson's disease. Parkinsonism & Related Disorders. 14: 633-5. PMID 18346926 DOI: 10.1016/j.parkreldis.2008.01.017 |
0.326 |
|
| 2008 |
Yust-Katz S, Sthneer S, Melamed E, Djaldetti R. Long-term Parkinson's disease--time for optimism. Biomedicine & Pharmacotherapy = Biomã©Decine & Pharmacothã©Rapie. 62: 233-5. PMID 18294809 DOI: 10.1016/j.biopha.2007.12.014 |
0.344 |
|
| 2008 |
Djaldetti R, Nageris BI, Lorberboym M, Treves TA, Melamed E, Yaniv E. [(123)I]-FP-CIT SPECT and olfaction test in patients with combined postural and rest tremor. Journal of Neural Transmission (Vienna, Austria : 1996). 115: 469-72. PMID 18250955 DOI: 10.1007/s00702-007-0851-0 |
0.315 |
|
| 2008 |
Hellmann MA, Sabach T, Melamed E, Djaldetti R. Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease. Biomedicine & Pharmacotherapy = Biomã©Decine & Pharmacothã©Rapie. 62: 250-2. PMID 17967525 DOI: 10.1016/j.biopha.2007.09.002 |
0.403 |
|
| 2007 |
Lev N, Melamed E, Offen D. Toxic causes of parkinsonism. Handbook of Clinical Neurology. 84: 385-98. PMID 18808959 DOI: 10.1016/S0072-9752(07)84050-4 |
0.402 |
|
| 2007 |
Melamed E, Ziv I, Djaldetti R. Management of motor complications in advanced Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 22: S379-84. PMID 18175400 DOI: 10.1002/mds.21680 |
0.381 |
|
| 2007 |
Djaldetti R, Treves TA, Ziv I, Melamed E, Lorberboym M. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with recurrent sudden falls: are such falls a distinct entity? Journal of Nuclear Medicine Technology. 35: 232-6. PMID 18006592 DOI: 10.2967/jnmt.107.040238 |
0.338 |
|
| 2007 |
Offen D, Barhum Y, Levy YS, Burshtein A, Panet H, Cherlow T, Melamed E. Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson's disease. Journal of Neural Transmission. Supplementum. 133-43. PMID 17982886 DOI: 10.1007/978-3-211-73574-9-16 |
0.384 |
|
| 2007 |
Litvan I, Chesselet MF, Gasser T, Di Monte DA, Parker D, Hagg T, Hardy J, Jenner P, Myers RH, Price D, Hallett M, Langston WJ, Lang AE, Halliday G, Rocca W, ... ... Melamed E, et al. The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. Journal of Neuropathology and Experimental Neurology. 66: 329-36. PMID 17483689 DOI: 10.1097/Nen.0B013E318053716A |
0.318 |
|
| 2007 |
Kan I, Ben-Zur T, Barhum Y, Levy YS, Burstein A, Charlow T, Bulvik S, Melamed E, Offen D. Dopaminergic differentiation of human mesenchymal stem cells--utilization of bioassay for tyrosine hydroxylase expression. Neuroscience Letters. 419: 28-33. PMID 17475405 DOI: 10.1016/j.neulet.2007.03.070 |
0.415 |
|
| 2007 |
Kan I, Melamed E, Offen D, Green P. Docosahexaenoic acid and arachidonic acid are fundamental supplements for the induction of neuronal differentiation. Journal of Lipid Research. 48: 513-7. PMID 17185746 DOI: 10.1194/jlr.C600022-JLR200 |
0.327 |
|
| 2007 |
Lev N, Djaldetti R, Melamed E. Initiation of symptomatic therapy in Parkinson's disease: Dopamine agonists versus levodopa Journal of Neurology. 254: 19-26. DOI: 10.1007/s00415-007-5004-8 |
0.387 |
|
| 2006 |
Melamed E, Djaldetti R. Camptocormia in Parkinson's disease. Journal of Neurology. 253: VII14-16. PMID 17131221 DOI: 10.1007/s00415-006-7004-5 |
0.371 |
|
| 2006 |
Lev N, Roncevic D, Roncevich D, Ickowicz D, Melamed E, Offen D. Role of DJ-1 in Parkinson's disease. Journal of Molecular Neuroscience : Mn. 29: 215-25. PMID 17085780 DOI: 10.1385/JMN:29:3:215 |
0.342 |
|
| 2006 |
Gilgun-Sherki Y, Melamed E, Offen D. Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state. Current Pharmaceutical Design. 12: 3509-19. PMID 17017944 DOI: 10.2174/138161206778343091 |
0.312 |
|
| 2006 |
Hellmann MA, Djaldetti R, Israel Z, Melamed E. Effect of deep brain subthalamic stimulation on camptocormia and postural abnormalities in idiopathic Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 2008-10. PMID 16972244 DOI: 10.1002/mds.21090 |
0.36 |
|
| 2006 |
Djaldetti R, Ziv I, Melamed E. The mystery of motor asymmetry in Parkinson's disease. The Lancet. Neurology. 5: 796-802. PMID 16914408 DOI: 10.1016/S1474-4422(06)70549-X |
0.329 |
|
| 2006 |
Dabby R, Djaldetti R, Shahmurov M, Treves TA, Gabai B, Melamed E, Sadeh M, Avinoach I. Skin biopsy for assessment of autonomic denervation in Parkinson's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 113: 1169-76. PMID 16835698 DOI: 10.1007/s00702-005-0431-0 |
0.336 |
|
| 2006 |
Oved D, Ziv I, Treves TA, Paleacu D, Melamed E, Djaldetti R. Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 1257-61. PMID 16685690 DOI: 10.1002/mds.20929 |
0.392 |
|
| 2006 |
Lev N, Melamed E, Offen D. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage. Neuroscience Letters. 399: 27-32. PMID 16584840 DOI: 10.1016/j.neulet.2005.09.086 |
0.32 |
|
| 2006 |
Hellmann MA, Panet H, Barhum Y, Melamed E, Offen D. Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neuroscience Letters. 395: 124-8. PMID 16359791 DOI: 10.1016/j.neulet.2005.10.097 |
0.364 |
|
| 2006 |
Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 510-4. PMID 16250023 DOI: 10.1002/mds.20748 |
0.396 |
|
| 2005 |
Levy YS, Gilgun-Sherki Y, Melamed E, Offen D. Therapeutic potential of neurotrophic factors in neurodegenerative diseases. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 19: 97-127. PMID 15807629 DOI: 10.2165/00063030-200519020-00003 |
0.36 |
|
| 2005 |
Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 365: 947-54. PMID 15766996 DOI: 10.1016/S0140-6736(05)71083-7 |
0.332 |
|
| 2005 |
Bahat-Stroomza M, Gilgun-Sherki Y, Offen D, Panet H, Saada A, Krool-Galron N, Barzilai A, Atlas D, Melamed E. A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease. The European Journal of Neuroscience. 21: 637-46. PMID 15733082 DOI: 10.1111/j.1460-9568.2005.03889.x |
0.439 |
|
| 2005 |
Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, Yebenes JD, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, ... ... Melamed E, et al. Erratum: Levodopa in the treatment of Parkinson's disease: Current controversies (Movement Disorders) (2004)) Movement Disorders. 20. DOI: 10.1002/Mds.20519 |
0.302 |
|
| 2004 |
Elkon H, Melamed E, Offen D. Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease. Journal of Molecular Neuroscience : Mn. 24: 387-400. PMID 15655261 DOI: 10.1385/JMN:24:3:387 |
0.378 |
|
| 2004 |
Levy YS, Stroomza M, Melamed E, Offen D. Embryonic and adult stem cells as a source for cell therapy in Parkinson's disease. Journal of Molecular Neuroscience : Mn. 24: 353-86. PMID 15655260 DOI: 10.1385/JMN:24:3:353 |
0.421 |
|
| 2004 |
Djaldetti R, Hellmann M, Melamed E. Bent knees and tiptoeing: late manifestations of end-stage Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 19: 1325-8. PMID 15389997 DOI: 10.1002/mds.20187 |
0.34 |
|
| 2004 |
Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Bonucelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, ... ... Melamed E, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Movement Disorders : Official Journal of the Movement Disorder Society. 19: 997-1005. PMID 15372588 DOI: 10.1002/Mds.20243 |
0.397 |
|
| 2004 |
Gilgun-Sherki Y, Djaldetti R, Melamed E, Offen D. Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease. The Pharmacogenomics Journal. 4: 291-306. PMID 15224083 DOI: 10.1038/sj.tpj.6500260 |
0.364 |
|
| 2004 |
Bulvik S, Ben-Zur T, Levy YS, Burshtein A, Melamed E, Offen D. Transcription Factors Analysis in Neuronal-Like Cells Derived from Adult Human Bone Marrow. Blood. 104: 4172-4172. DOI: 10.1182/Blood.V104.11.4172.4172 |
0.354 |
|
| 2003 |
Djaldetti R, Giladi N, Hassin-Baer S, Shabtai H, Melamed E. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Clinical Neuropharmacology. 26: 322-6. PMID 14646613 DOI: 10.1097/00002826-200311000-00012 |
0.355 |
|
| 2003 |
Levy YS, Merims D, Panet H, Barhum Y, Melamed E, Offen D. Induction of neuron-specific enolase promoter and neuronal markers in differentiated mouse bone marrow stromal cells. Journal of Molecular Neuroscience : Mn. 21: 121-32. PMID 14593212 DOI: 10.1385/JMN:21:2:121 |
0.347 |
|
| 2003 |
Gilgun-Sherki Y, Melamed E, Mechoulam R, Offen D. The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacology & Toxicology. 93: 66-70. PMID 12899667 DOI: 10.1034/J.1600-0773.2003.930202.X |
0.414 |
|
| 2003 |
Merims D, Djaldetti R, Melamed E. Waiting for ON: a major problem in patients with Parkinson disease and ON/OFF motor fluctuations. Clinical Neuropharmacology. 26: 196-8. PMID 12897640 DOI: 10.1097/00002826-200307000-00009 |
0.306 |
|
| 2003 |
Barzilai A, Melamed E. Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease. Trends in Molecular Medicine. 9: 126-32. PMID 12657434 DOI: 10.1016/S1471-4914(03)00020-0 |
0.38 |
|
| 2003 |
Lev N, Melamed E, Offen D. Apoptosis and Parkinson's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 27: 245-50. PMID 12657363 DOI: 10.1016/S0278-5846(03)00019-8 |
0.382 |
|
| 2003 |
Djaldetti R, Treves TA, Merims D, Sroka H, Melamed E. Effect of late initiation of levodopa treatment in patients with long-standing Parkinson's disease. Clinical Neuropharmacology. 26: 24-7. PMID 12567161 DOI: 10.1097/00002826-200301000-00006 |
0.362 |
|
| 2002 |
Levy YS, Streifler JY, Panet H, Melamed E, Offen D. Hemin-induced apoptosis in PC12 and neuroblastoma cells: implications for local neuronal death associated with intracerebral hemorrhage. Neurotoxicity Research. 4: 609-616. PMID 12709299 DOI: 10.1080/1029842021000045624 |
0.303 |
|
| 2002 |
Shirvan A, Kimron M, Holdengreber V, Ziv I, Ben-Shaul Y, Melamed S, Melamed E, Barzilai A, Solomon AS. Anti-semaphorin 3A antibodies rescue retinal ganglion cells from cell death following optic nerve axotomy. The Journal of Biological Chemistry. 277: 49799-807. PMID 12376549 DOI: 10.1074/jbc.M204793200 |
0.301 |
|
| 2002 |
Djaldetti R, Melamed E. New drugs in the future treatment of Parkinson's disease. Journal of Neurology. 249: II30-5. PMID 12375061 DOI: 10.1007/s00415-002-1206-2 |
0.359 |
|
| 2002 |
Djaldetti R, Ziv I, Melamed E. The effect of deprenyl washout in patients with long-standing Parkinson's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 109: 797-803. PMID 12111469 DOI: 10.1007/s007020200066 |
0.326 |
|
| 2001 |
Ziv I, Shirvan A, Offen D, Barzilai A, Melamed E. Molecular biology of dopamine-induced apoptosis : possible implications for Parkinson's disease. Methods in Molecular Medicine. 62: 73-87. PMID 21318769 DOI: 10.1385/1-59259-142-6:73 |
0.37 |
|
| 2001 |
Elkon H, Melamed E, Offen D. 6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease. Cellular and Molecular Neurobiology. 21: 771-81. PMID 12043847 DOI: 10.1023/A:1015160323009 |
0.359 |
|
| 2001 |
Offen D, Shtaif B, Hadad D, Weizman A, Melamed E, Gil-Ad I. Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease. Neuroscience Letters. 316: 129-32. PMID 11744219 DOI: 10.1016/S0304-3940(01)02344-8 |
0.417 |
|
| 2001 |
Barzilai A, Melamed E, Shirvan A. Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease? Cellular and Molecular Neurobiology. 21: 215-35. PMID 11569535 DOI: 10.1023/A:1010991020245 |
0.427 |
|
| 2001 |
Djaldetti R, Melamed E. New therapies for Parkinson's disease. Journal of Neurology. 248: 357-62. PMID 11437155 DOI: 10.1007/S004150170174 |
0.38 |
|
| 2001 |
Djaldetti R, Rosmarin V, Ziv I, Melamed E. The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease. Clinical Neuropharmacology. 24: 95-8. PMID 11307044 DOI: 10.1097/00002826-200103000-00005 |
0.371 |
|
| 2001 |
Panet H, Barzilai A, Daily D, Melamed E, Offen D. Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells. Journal of Neurochemistry. 77: 391-8. PMID 11299301 DOI: 10.1046/j.1471-4159.2001.00213.x |
0.342 |
|
| 2001 |
Albanese A, Bonuccelli U, Brefel C, Chaudhuri KR, Colosimo C, Eichhorn T, Melamed E, Pollak P, Van Laar T, Zappia M. Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 16: 197-201. PMID 11295770 DOI: 10.1002/Mds.1069 |
0.308 |
|
| 2001 |
Offen D, Panet H, Galili-Mosberg R, Melamed E. Catechol-O-methyltransferase decreases levodopa toxicity in vitro. Clinical Neuropharmacology. 24: 27-30. PMID 11290879 DOI: 10.1097/00002826-200101000-00006 |
0.307 |
|
| 2001 |
Daily D, Vlamis-Gardikas A, Offen D, Mittelman L, Melamed E, Holmgren A, Barzilai A. Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by dual activation of the ras-phosphoinositide 3-kinase and jun n-terminal kinase pathways. The Journal of Biological Chemistry. 276: 21618-26. PMID 11290748 DOI: 10.1074/jbc.M101400200 |
0.302 |
|
| 2001 |
Daily D, Vlamis-Gardikas A, Offen D, Mittelman L, Melamed E, Holmgren A, Barzilai A. Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by activating NF-kappa B via Ref-1. The Journal of Biological Chemistry. 276: 1335-44. PMID 11035035 DOI: 10.1074/jbc.M008121200 |
0.311 |
|
| 2000 |
Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clinical Neuropharmacology. 23: 324-30. PMID 11575866 DOI: 10.1097/00002826-200011000-00005 |
0.367 |
|
| 2000 |
Galili R, Mosberg, Gil-Ad I, Weizman A, Melamed E, Offen D. Haloperidol-induced neurotoxicity--possible implications for tardive dyskinesia. Journal of Neural Transmission (Vienna, Austria : 1996). 107: 479-90. PMID 11215758 DOI: 10.1007/S007020070089 |
0.367 |
|
| 2000 |
Barzilai A, Zilkha-Falb R, Daily D, Stern N, Offen D, Ziv I, Melamed E, Shirvan A. The molecular mechanism of dopamine-induced apoptosis: identification and characterization of genes that mediate dopamine toxicity. Journal of Neural Transmission. Supplementum. 59-76. PMID 11205158 DOI: 10.1007/978-3-7091-6301-6_4 |
0.435 |
|
| 2000 |
Offen D, Elkon H, Melamed E. Apoptosis as a general cell death pathway in neurodegenerative diseases. Journal of Neural Transmission. Supplementum. 153-66. PMID 11128605 DOI: 10.1007/978-3-7091-6284-2_13 |
0.339 |
|
| 2000 |
Shirvan A, Shina R, Ziv I, Melamed E, Barzilai A. Induction of neuronal apoptosis by Semaphorin3A-derived peptide. Brain Research. Molecular Brain Research. 83: 81-93. PMID 11072098 DOI: 10.1016/S0169-328X(00)00198-4 |
0.307 |
|
| 2000 |
Merims D, Galili-Mosberg R, Melamed E. Is there addiction to levodopa in patients with Parkinson's disease? Movement Disorders : Official Journal of the Movement Disorder Society. 15: 1014-6. PMID 11009217 DOI: 10.1002/1531-8257(200009)15:5<1014::Aid-Mds1041>3.0.Co;2-O |
0.357 |
|
| 2000 |
Melamed E, Offen D, Shirvan A, Ziv I. Levodopa--an exotoxin or a therapeutic drug? Journal of Neurology. 247: II135-9. PMID 10991660 DOI: 10.1007/Pl00022914 |
0.395 |
|
| 2000 |
Zilkha-Falb R, Barzilai A, Djaldeti R, Ziv I, Melamed E, Shirvan A. Involvement of T-complex protein-1delta in dopamine triggered apoptosis in chick embryo sympathetic neurons. The Journal of Biological Chemistry. 275: 36380-7. PMID 10954701 DOI: 10.1074/jbc.M001692200 |
0.375 |
|
| 2000 |
Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE, Gozes I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Research. 854: 257-62. PMID 10784133 DOI: 10.1016/S0006-8993(99)02375-6 |
0.577 |
|
| 1999 |
Agid Y, Ahlskog E, Albanese A, Calne D, Chase T, De Yebenes J, Factor S, Fahn S, Gershanik O, Goetz C, Koller W, Kurth M, Lang A, Lees A, Lewitt P, ... ... Melamed E, et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 911-3. PMID 10584663 DOI: 10.1002/1531-8257(199911)14:6<911::Aid-Mds1001>3.0.Co;2-H |
0.384 |
|
| 1999 |
Melamed E, Zoldan J, Galili-Mosberg R, Ziv I, Djaldetti R. Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa. Journal of Neural Transmission. Supplementum. 56: 173-83. PMID 10370911 DOI: 10.1007/978-3-7091-6360-3_11 |
0.362 |
|
| 1999 |
Djaldetti R, Mosberg-Galili R, Sroka H, Merims D, Melamed E. Camptocormia (bent spine) in patients with Parkinson's disease--characterization and possible pathogenesis of an unusual phenomenon. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 443-7. PMID 10348467 DOI: 10.1002/1531-8257(199905)14:3<443::Aid-Mds1009>3.0.Co;2-G |
0.328 |
|
| 1999 |
Merims D, Ziv I, Djaldetti R, Melamed E. Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease. Lancet. 353: 1764-5. PMID 10347995 DOI: 10.1016/S0140-6736(99)00120-8 |
0.366 |
|
| 1999 |
Daily D, Barzilai A, Offen D, Kamsler A, Melamed E, Ziv I. The involvement of p53 in dopamine-induced apoptosis of cerebellar granule neurons and leukemic cells overexpressing p53. Cellular and Molecular Neurobiology. 19: 261-76. PMID 10081609 DOI: 10.1023/A:1006933312401 |
0.386 |
|
| 1999 |
Ziv I, Avraham M, Dabby R, Zoldan J, Djaldetti R, Melamed E. Early-occurrence of manual motor blocks in Parkinson's disease: a quantitative assessment. Acta Neurologica Scandinavica. 99: 106-11. PMID 10071169 DOI: 10.1111/J.1600-0404.1999.Tb00666.X |
0.333 |
|
| 1999 |
Offen D, Gorodin S, Melamed E, Hanania J, Malik Z. Dopamine-melanin is actively phagocytized by PC12 cells and cerebellar granular cells: possible implications for the etiology of Parkinson's disease. Neuroscience Letters. 260: 101-4. PMID 10025709 DOI: 10.1016/S0304-3940(98)00950-1 |
0.407 |
|
| 1999 |
Giladi N, Melamed E. Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 158-9. PMID 9918362 DOI: 10.1002/1531-8257(199901)14:1<158::Aid-Mds1028>3.0.Co;2-Q |
0.314 |
|
| 1998 |
Ziv I, Avraham M, Michaelov Y, Djaldetti R, Dressler R, Zoldan J, Melamed E. Enhanced fatigue during motor performance in patients with Parkinson's disease. Neurology. 51: 1583-6. PMID 9855505 DOI: 10.1212/Wnl.51.6.1583 |
0.352 |
|
| 1998 |
Ziv I, Melamed E. Role of apoptosis in the pathogenesis of Parkinson's disease: A novel therapeutic opportunity? Movement Disorders : Official Journal of the Movement Disorder Society. 13: 865-70. PMID 9827608 DOI: 10.1002/mds.870130602 |
0.328 |
|
| 1998 |
Melamed E, Offen D, Shirvan A, Djaldetti R, Barzilai A, Ziv I. Levodopa toxicity and apoptosis. Annals of Neurology. 44: S149-54. PMID 9749587 DOI: 10.1002/Ana.410440722 |
0.397 |
|
| 1998 |
Djaldetti R, Melamed E. Management of response fluctuations: practical guidelines. Neurology. 51: S36-40. PMID 9711979 DOI: 10.1212/Wnl.51.2_Suppl_2.S36 |
0.394 |
|
| 1998 |
Hochman A, Sternin H, Gorodin S, Korsmeyer S, Ziv I, Melamed E, Offen D. Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice. Journal of Neurochemistry. 71: 741-8. PMID 9681465 DOI: 10.1046/J.1471-4159.1998.71020741.X |
0.314 |
|
| 1998 |
Djaldetti R, Ziv I, Melamed E. Extreme anticipation in young-onset Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 599-600. PMID 9613762 DOI: 10.1002/mds.870130339 |
0.339 |
|
| 1998 |
Offen D, Beart PM, Cheung NS, Pascoe CJ, Hochman A, Gorodin S, Melamed E, Bernard R, Bernard O. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America. 95: 5789-94. PMID 9576963 DOI: 10.1073/Pnas.95.10.5789 |
0.369 |
|
| 1998 |
Shirvan A, Ziv I, Zilkha-Falb R, Machlyn T, Barzilai A, Melamed E. Expression of cell cycle-related genes during neuronal apoptosis: is there a distinct pattern? Neurochemical Research. 23: 767-77. PMID 9566617 DOI: 10.1023/A:1022415611545 |
0.322 |
|
| 1997 |
Ziv I, Offen D, Haviv R, Stein R, Panet H, Zilkha-Falb R, Shirvan A, Barzilai A, Melamed E. The proto-oncogene Bcl-2 inhibits cellular toxicity of dopamine: possible implications for Parkinson's disease. Apoptosis : An International Journal On Programmed Cell Death. 2: 149-55. PMID 14646549 DOI: 10.1023/A:1026408313758 |
0.424 |
|
| 1997 |
Ziv I, Offen D, Barzilai A, Haviv R, Stein R, Zilkha-Falb R, Shirvan A, Melamed E. Modulation of control mechanisms of dopamine-induced apoptosis--a future approach to the treatment of Parkinson's disease? Journal of Neural Transmission. Supplementum. 49: 195-202. PMID 9266428 DOI: 10.1007/978-3-7091-6844-8_20 |
0.43 |
|
| 1997 |
Ziv I, Barzilai A, Offen D, Nardi N, Melamed E. Nigrostriatal neuronal death in Parkinson's disease--a passive or an active genetically-controlled process? Journal of Neural Transmission. Supplementum. 49: 69-76. PMID 9266415 DOI: 10.1007/978-3-7091-6844-8_7 |
0.419 |
|
| 1997 |
Shirvan A, Ziv I, Machlin T, Zilkha-Falb R, Melamed E, Barzilai A. Two waves of cyclin B and proliferating cell nuclear antigen expression during dopamine-triggered neuronal apoptosis. Journal of Neurochemistry. 69: 539-49. PMID 9231711 DOI: 10.1046/J.1471-4159.1997.69020539.X |
0.336 |
|
| 1997 |
Offen D, Ziv I, Barzilai A, Gorodin S, Glater E, Hochman A, Melamed E. Dopamine-melanin induces apoptosis in PC12 cells; possible implications for the etiology of Parkinson's disease. Neurochemistry International. 31: 207-16. PMID 9220453 DOI: 10.1016/S0197-0186(96)00150-7 |
0.393 |
|
| 1997 |
Offen D, Ziv I, Panet H, Wasserman L, Stein R, Melamed E, Barzilai A. Dopamine-induced apoptosis is inhibited in PC12 cells expressing Bcl-2. Cellular and Molecular Neurobiology. 17: 289-304. PMID 9187486 DOI: 10.1023/A:1026390201168 |
0.429 |
|
| 1997 |
Shirvan A, Ziv I, Barzilai A, Djaldeti R, Zilkh-Falb R, Michlin T, Melamed E. Induction of mitosis-related genes during dopamine-triggered apoptosis in sympathetic neurons. Journal of Neural Transmission. Supplementum. 50: 67-78. PMID 9120426 DOI: 10.1007/978-3-7091-6842-4_8 |
0.399 |
|
| 1997 |
Zilkha-Falb R, Ziv I, Nardi N, Offen D, Melamed E, Barzilai A. Monoamine-induced apoptotic neuronal cell death. Cellular and Molecular Neurobiology. 17: 101-18. PMID 9118202 DOI: 10.1023/A:1026333222008 |
0.394 |
|
| 1997 |
Ziv I, Zilkha-Falb R, Offen D, Shirvan A, Barzilai A, Melamed E. Levodopa induces apoptosis in cultured neuronal cells--a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Movement Disorders : Official Journal of the Movement Disorder Society. 12: 17-23. PMID 8990049 DOI: 10.1002/mds.870120105 |
0.397 |
|
| 1997 |
Zilkha-Falb R, Shirvan A, Djaldeti R, Ziv I, Machlin T, Melamed E, Barzilai A. Induction of T-complex protein-1 (TCP-1) expression during dopamine-triggered neuronal apoptosis in chick embryo sympathetic neurons Neuroscience Letters. 237. DOI: 10.1016/S0304-3940(97)90226-3 |
0.338 |
|
| 1997 |
Offen D, Beart P, Choung S, Pascoe C, Hochman A, Gorodin S, Melamed E, Bernard R, Bernard O. Transgenic mice expressing human BCL-2 in their neurons are resistant to neurotoxicity of 6-OH-dopamine and MPTP Neuroscience Letters. 237: S38. DOI: 10.1016/S0304-3940(97)90155-5 |
0.343 |
|
| 1996 |
Djaldetti R, Atlas D, Melamed E. Effect of subcutaneous administration of levodopa ethyl ester, a soluble prodrug of levodopa, on dopamine metabolism in rodent striatum: implication for treatment of Parkinson's disease. Clinical Neuropharmacology. 19: 65-71. PMID 8867519 DOI: 10.1097/00002826-199619010-00005 |
0.435 |
|
| 1996 |
Offen D, Ziv I, Sternin H, Melamed E, Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Experimental Neurology. 141: 32-9. PMID 8797665 DOI: 10.1006/Exnr.1996.0136 |
0.405 |
|
| 1996 |
Djaldetti R, Baron J, Ziv I, Melamed E. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology. 46: 1051-4. PMID 8780089 DOI: 10.1212/WNL.46.4.1051 |
0.304 |
|
| 1996 |
Ziv I, Barzilai A, Offen D, Stein R, Achiron A, Melamed E. Dopamine-induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease? Advances in Neurology. 69: 229-33. PMID 8615132 |
0.306 |
|
| 1996 |
Djaldetti R, Melamed E. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease. Annals of Neurology. 39: 400-4. PMID 8602763 DOI: 10.1002/ana.410390321 |
0.36 |
|
| 1995 |
Djaldetti R, Koren M, Ziv I, Achiron A, Melamed E. Effect of cisapride on response fluctuations in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 10: 81-4. PMID 7885359 DOI: 10.1002/mds.870100113 |
0.338 |
|
| 1995 |
Offen D, Ziv I, Gorodin S, Barzilai A, Malik Z, Melamed E. Dopamine-induced programmed cell death in mouse thymocytes. Biochimica Et Biophysica Acta. 1268: 171-7. PMID 7662705 DOI: 10.1016/0167-4889(95)00075-4 |
0.363 |
|
| 1995 |
Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology. 45: 1305-8. PMID 7617188 DOI: 10.1212/WNL.45.7.1305 |
0.311 |
|
| 1994 |
Ziv I, Achiron A, Djaldetti R, Abraham M, Melamed E. Can nimodipine affect progression of motor neuron disease? A double-blind pilot study. Clinical Neuropharmacology. 17: 423-8. PMID 9316691 DOI: 10.1097/00002826-199410000-00004 |
0.335 |
|
| 1994 |
Achiron A, Margalit R, Hershkoviz R, Markovits D, Reshef T, Melamed E, Cohen IR, Lider O. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. The Journal of Clinical Investigation. 93: 600-5. PMID 8113397 DOI: 10.1172/Jci117012 |
0.303 |
|
| 1994 |
Ziv I, Melamed E, Nardi N, Luria D, Achiron A, Offen D, Barzilai A. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons--a possible novel pathogenetic mechanism in Parkinson's disease. Neuroscience Letters. 170: 136-40. PMID 8041491 DOI: 10.1016/0304-3940(94)90258-5 |
0.419 |
|
| 1994 |
Djaldetti R, Achiron A, Ziv I, Melamed E. First emergence of "delayed-on" and "dose failure" phenomena in a patient with Parkinson's disease following vagotomy. Movement Disorders : Official Journal of the Movement Disorder Society. 9: 582-3. PMID 7990855 DOI: 10.1002/mds.870090513 |
0.32 |
|
| 1994 |
Achiron A, Gilad R, Margalit R, Gabbay U, Sarova-Pinhas I, Cohen IR, Melamed E, Lider O, Noy S, Ziv I. Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action. Journal of Neurology, Neurosurgery, and Psychiatry. 57: 57-61. PMID 7964856 DOI: 10.1136/jnnp.57.Suppl.57 |
0.304 |
|
| 1993 |
Ziv I, Achiron A, Djaldetti R, Dressler R, Melamed E. Short-term beneficial effect of deprenyl monotherapy in early Parkinson's disease: a quantitative assessment. Clinical Neuropharmacology. 16: 54-60. PMID 8422657 DOI: 10.1097/00002826-199302000-00006 |
0.337 |
|
| 1993 |
Achiron A, Ziv I, Goren M, Goldberg H, Zoldan Y, Sroka H, Melamed E. Primary progressive freezing gait. Movement Disorders : Official Journal of the Movement Disorder Society. 8: 293-7. PMID 8341293 DOI: 10.1002/mds.870080307 |
0.33 |
|
| 1993 |
Zoldan J, Friedberg G, Goldberg-Stern H, Melamed E. Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet. 341: 562-3. PMID 8094803 DOI: 10.1016/0140-6736(93)90327-D |
0.337 |
|
| 1992 |
Melamed E. Biochemical and functional differences between dopamine formed from endogenous tyrosine and exogenous L-dopa in nigrostriatal dopaminergic neurons. Neurochemistry International. 20: 115S-117S. PMID 1365408 DOI: 10.1016/0197-0186(92)90222-D |
0.416 |
|
| 1991 |
Melamed E, Achiron A, Shapira A, Davidovicz S. Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: An additional tardive syndrome? Clinical Neuropharmacology. 14: 273-278. PMID 1676933 DOI: 10.1097/00002826-199106000-00013 |
0.375 |
|
| 1990 |
Melamed E, Rosenthal J, Youdim MB. Immunity of fetal mice to prenatal administration of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Journal of Neurochemistry. 55: 1427-31. PMID 2398363 DOI: 10.1111/j.1471-4159.1990.tb03156.x |
0.362 |
|
| 1988 |
Melamed E. Brain grafting may reverse loss of responsiveness to levodopa therapy in Parkinson's disease. Clinical Neuropharmacology. 11: 77-82. PMID 3280129 DOI: 10.1097/00002826-198802000-00008 |
0.433 |
|
| 1988 |
Siegal T, Melamed E, Sandbank U, Catane R. Early and delayed neurotoxicity of mitoxantrone and doxorubicin following subarachnoid injection. Journal of Neuro-Oncology. 6: 135-40. PMID 3225635 DOI: 10.1007/BF02327389 |
0.313 |
|
| 1988 |
Pikarsky E, Melamed E, Rosenthal J, Uzzan A, Michowiz SD. The neurotoxin MPTP does not affect striatal superoxide dismutase activity in mice. Neuroscience Letters. 82: 327-31. PMID 2827077 DOI: 10.1016/0304-3940(87)90277-1 |
0.383 |
|
| 1987 |
Kidron D, Melamed E. Forms of dystonia in patients with Parkinson's disease Neurology. 37: 1009-1009. PMID 3587617 DOI: 10.1212/Wnl.37.6.1009 |
0.357 |
|
| 1987 |
Melamed E, Soffer D, Rosenthal J, Pikarsky E, Reches A. Effect of intrastriatal and intranigral administration of synthetic neuromelanin on the dopaminergic neurotoxicity of MPTP in rodents. Neuroscience Letters. 83: 41-6. PMID 3502019 DOI: 10.1016/0304-3940(87)90213-8 |
0.38 |
|
| 1987 |
Melamed E, Pikarski E, Goldberg A, Rosenthal J, Uzzan A, Conforti N. Effect of serotonergic, corticostriatal and kainic acid lesions on the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in mice. Brain Research. 399: 178-80. PMID 3492237 DOI: 10.1016/0006-8993(86)90615-3 |
0.376 |
|
| 1986 |
Melamed E, Youdim MB, Rosenthal J, Spanier I, Uzzan A, Globus M. In vivo effect of MPTP on monoamine oxidase activity in mouse striatum. Brain Research. 359: 360-3. PMID 3878183 DOI: 10.1016/0006-8993(85)91451-9 |
0.374 |
|
| 1986 |
Melamed E, Martinovits G, Pikarsky E, Rosenthal J, Uzzan A. Diphenylhydantoin and phenobarbital suppress the dopaminergic neurotoxicity of MPTP in mice. European Journal of Pharmacology. 128: 255-257. PMID 3491762 DOI: 10.1016/0014-2999(86)90773-9 |
0.371 |
|
| 1986 |
Martinovits G, Melamed E, Cohen O, Rosenthal J, Uzzan A. Systemic administration of antioxidants does not protect mice against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP). Neuroscience Letters. 69: 192-7. PMID 3489911 DOI: 10.1016/0304-3940(86)90602-6 |
0.328 |
|
| 1986 |
Melamed E, Bitton V, Zelig O. Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy. Clinical Neuropharmacology. 9: 182-188. PMID 3085928 DOI: 10.1097/00002826-198604000-00009 |
0.305 |
|
| 1986 |
Melamed E. Initiation of Levodopa Therapy in Parkinsonian Patients Should Be Delayed Until the Advanced Stages of the Disease Jama Neurology. 43: 402-405. PMID 3082315 DOI: 10.1001/Archneur.1986.00520040080025 |
0.316 |
|
| 1986 |
Melamed E, Globus M, Mildworf B. Regional cerebral blood flow in patients with Parkinson's disease under chronic levodopa therapy: measurements during "on" and "off" response fluctuations. Journal of Neurology, Neurosurgery, and Psychiatry. 49: 1301-1304. PMID 3025375 DOI: 10.1136/Jnnp.49.11.1301 |
0.345 |
|
| 1985 |
Globus M, Mildworf B, Melamed E. Cerebral blood flow and cognitive impairment in Parkinson's disease Neurology. 35: 1135-1135. PMID 4022347 DOI: 10.1212/Wnl.35.8.1135 |
0.317 |
|
| 1985 |
Melamed E, Hefti F. Altered pharmacokinetics of L-dopa metabolism. Neurology. 35: 939-41. PMID 4000502 DOI: 10.1212/Wnl.35.6.939-A |
0.484 |
|
| 1985 |
Melamed E, Rosenthal J, Cohen O, Uzzan A, Globus M. Amphetamine, but not reserpine, protects mice against dopaminergic neurotoxicity of MPTP. Neuropharmacology. 24: 923-5. PMID 3877249 DOI: 10.1016/0028-3908(85)90047-4 |
0.363 |
|
| 1985 |
Melamed E, Rosenthal J, Cohen O, Mordechai G, Uzzan A. Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP. European Journal of Pharmacology. 116: 179-181. PMID 3876943 DOI: 10.1016/0014-2999(85)90201-8 |
0.376 |
|
| 1985 |
Melamed E, Rosenthal J, Globus M, Cohen O, Frucht Y, Uzzan A. Mesolimbic dopaminergic neurons are not spared by MPTP neurotoxicity in mice. European Journal of Pharmacology. 114: 97-100. PMID 3876229 DOI: 10.1016/0014-2999(85)90528-X |
0.38 |
|
| 1985 |
Melamed E, Rosenthal J, Globus M, Cohen O, Uzzan A. Suppression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine and L-DOPA. Brain Research. 342: 401-4. PMID 3876139 DOI: 10.1016/0006-8993(85)91146-1 |
0.413 |
|
| 1985 |
Hefti F, Enz A, Melamed E. Partial lesions of the nigrostriatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs. Neuropharmacology. 24: 19-23. PMID 2858830 DOI: 10.1016/0028-3908(85)90090-5 |
0.535 |
|
| 1984 |
Melamed E, Frucht Y, Lemor M, Uzzan A, Rosenthal Y. Dopamine turnover in rat retina: A 24-hour light-dependent rhythm Brain Research. 305: 148-151. PMID 6744054 DOI: 10.1016/0006-8993(84)91130-2 |
0.308 |
|
| 1984 |
Melamed E, Hefti F, Bitton V, Globus M. Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism. Neurology. 34: 1566-70. PMID 6504328 DOI: 10.1212/WNL.34.12.1566 |
0.58 |
|
| 1983 |
Melamed E, Durst R, Frucht Y, Globus M. Differential effect of acute and chronic haloperidol administration on dopamine turnover in rat nigrostriatal and retinal dopaminergic neurons. European Journal of Pharmacology. 89: 279-282. PMID 6873163 DOI: 10.1016/0014-2999(83)90506-X |
0.376 |
|
| 1983 |
Melamed E, Globus M, Friedlender E, Rosenthal J. Chronic L‐dopa administration decreases striatal accumulation of dopamine from exogenous L‐dopa in rats with intact nigrostriatal projections Neurology. 33: 950-950. PMID 6683384 DOI: 10.1212/Wnl.33.7.950 |
0.381 |
|
| 1983 |
Globus M, Melamed E, Conforti N. Effect of decortication on striatal dopamine turnover. Clinical Neuropharmacology. 6: 247-252. PMID 6627233 DOI: 10.1097/00002826-198309000-00007 |
0.416 |
|
| 1983 |
Globus M, Melamed E. Combined administration of direct dopamine receptor agonists and L-dopa does not interfere with utilization of exogenous L-dopa in rat corpus striatum. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 7: 211-5. PMID 6310691 DOI: 10.1016/0278-5846(83)90109-4 |
0.402 |
|
| 1982 |
Lichtensteiger W, Hefti F, Felix D, Huwyler T, Melamed E, Schlumpf M. Stimulation of nigrostriatal dopamine neurones by nicotine. Neuropharmacology. 21: 963-8. PMID 7145035 DOI: 10.1016/0028-3908(82)90107-1 |
0.551 |
|
| 1982 |
Melamed E, Hefti F, Bird ED. Huntington chorea is not associated with hyperactivity of nigrostriatal dopaminergic neurons: studies in postmortem tissues and in rats with kainic acid lesions. Neurology. 32: 640-4. PMID 6211637 DOI: 10.1212/WNL.32.6.640 |
0.597 |
|
| 1982 |
Growdon JH, Melamed E, Logue M, Hefti F, Wurtman RJ. Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease. Life Sciences. 30: 827-32. PMID 6175872 DOI: 10.1016/0024-3205(82)90596-3 |
0.714 |
|
| 1982 |
Melamed E, Hefti F, Wurtman RJ. Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model. Israel Journal of Medical Sciences. 18: 159-63. PMID 6121770 |
0.568 |
|
| 1982 |
Hefti F, Melamed E. Chronic dopa feeding of mice Neurology. 32: 685-685. DOI: 10.1212/WNL.32.6.685 |
0.465 |
|
| 1981 |
Hefti F, Melamed E. Dopamine release in rat striatum after administration of L-dope as studied with in vivo electrochemistry. Brain Research. 225: 333-46. PMID 7306794 DOI: 10.1016/0006-8993(81)90840-4 |
0.579 |
|
| 1981 |
Hefti F, Melamed E, Wurtman RJ. The site of dopamine formation in rat striatum after L-dopa administration. The Journal of Pharmacology and Experimental Therapeutics. 217: 189-97. PMID 7205652 |
0.554 |
|
| 1981 |
Melamed E, Hefti F, Pettibone DJ, Liebman J, Wurtman RJ. Aromatic L-amino acid decarboxylase in rat corpus striatum: implications for action of L-dopa in parkinsonism. Neurology. 31: 651-5. PMID 7195482 DOI: 10.1212/WNL.31.6.651 |
0.747 |
|
| 1981 |
Hefti F, Melamed E, Bhawan J, Wurtman RJ. Long-term administration of L-DOPA does not damage dopaminergic neurons in the mouse Neurology. 31: 1194-1194. DOI: 10.1212/WNL.31.9.1194 |
0.653 |
|
| 1981 |
Hefti F, Melamed E. Reply from Hefti and Melamed Trends in Neurosciences. 4: 150. DOI: 10.1016/0166-2236(81)90050-3 |
0.423 |
|
| 1980 |
Melamed E, Hefti F, Wurtman RJ. Decarboxylation of exogenous L-DOPA in rat striatum after lesions of the dopaminergic nigrostriatal neurons: the role of striatal capillaries. Brain Research. 198: 244-8. PMID 7407592 DOI: 10.1016/0006-8993(80)90363-7 |
0.668 |
|
| 1980 |
Melamed E, Hefti F, Wurtman RJ. Diminished decarboxylation of L-DOPA in rat striatum after intrastriatal injections of kainic acid. Neuropharmacology. 19: 409-11. PMID 7383284 DOI: 10.1016/0028-3908(80)90194-X |
0.662 |
|
| 1980 |
Melamed E, Hefti F, Wurtman RJ. L-3,4-Dihydroxyphenylalanine and L-5-hydroxytryptophan decarboxylase activities in rat striatum: effect of selective destruction of dopaminergic or serotoninergic input. Journal of Neurochemistry. 34: 1753-6. PMID 7381499 DOI: 10.1111/j.1471-4159.1980.tb11270.x |
0.608 |
|
| 1980 |
Melamed E, Glaeser B, Growdon JH, Wurtman RJ. Plasma tyrosine in normal humans: effects of oral tyrosine and protein-containing meals. Journal of Neural Transmission. 47: 299-306. PMID 7190187 DOI: 10.1007/BF01247323 |
0.579 |
|
| 1980 |
Hefti F, Melamed E, Sahakian BJ, Wurtman RJ. Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA. Pharmacology, Biochemistry, and Behavior. 12: 185-8. PMID 7189592 DOI: 10.1016/0091-3057(80)90353-6 |
0.684 |
|
| 1980 |
Hefti F, Melamed E, Wurtman RJ. The decarboxylation of DOPA in the parkinsonian brain: in vivo studies on an animal model. Journal of Neural Transmission. Supplementum. 95-101. PMID 6776238 DOI: 10.1007/978-3-7091-8582-7_10 |
0.667 |
|
| 1980 |
Melamed E, Hefti F, Wurtman RJ. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Annals of Neurology. 8: 558-63. PMID 6260009 DOI: 10.1002/ana.410080603 |
0.68 |
|
| 1980 |
Melamed E, Hefti F, Wurtman RJ. Tyrosine administration increases striatal dopamine release in rats with partial nigrostriatal lesions. Proceedings of the National Academy of Sciences of the United States of America. 77: 4305-9. PMID 6254020 DOI: 10.1073/PNAS.77.7.4305 |
0.663 |
|
| 1980 |
Wurtman RJ, Hefti F, Melamed E. Precursor control of neurotransmitter synthesis. Pharmacological Reviews. 32: 315-35. PMID 6115400 |
0.491 |
|
| 1980 |
Hefti F, Melamed E, Wurtman RJ. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Research. 195: 123-37. PMID 6105003 DOI: 10.1016/0006-8993(80)90871-9 |
0.676 |
|
| 1980 |
Melamed E, Hefti F, Liebman J, Schlosberg AJ, Wurtman RJ. Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease. Nature. 283: 772-4. PMID 6101905 DOI: 10.1038/283772A0 |
0.688 |
|
| 1980 |
Hefti F, Melamed E. l-DOPA's mechanism of action in Parkinson's disease Trends in Neurosciences. 3: 229-231. DOI: 10.1016/S0166-2236(80)80070-1 |
0.549 |
|
| 1979 |
Glaeser BS, Melamed E, Growdon JH, Wurtman RJ. Elevation of plasma tyrosine after a single oral dose of L-tyrosine. Life Sciences. 25: 265-71. PMID 481129 DOI: 10.1016/0024-3205(79)90294-7 |
0.56 |
|
| 1979 |
Lavy S, Melamed E, Cooper G, Bentin S, Rinot Y. Regional cerebral blood flow in patients with Parkinson's disease. Archives of Neurology. 36: 344-8. PMID 454231 DOI: 10.1001/archneur.1979.00500420054005 |
0.361 |
|
| 1979 |
Melamed E. Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease. Jama Neurology. 36: 308-310. PMID 444100 DOI: 10.1001/Archneur.1979.00500410086014 |
0.351 |
|
| 1979 |
Moskowitz MA, Reinhard JF, Romero J, Melamed E, Pettibone DJ. Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine? Lancet. 2: 883-5. PMID 90971 DOI: 10.1016/S0140-6736(79)92692-8 |
0.616 |
|
| Show low-probability matches. |